{"id":697566,"date":"2024-05-06T18:24:02","date_gmt":"2024-05-06T18:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=697566"},"modified":"2024-05-06T18:24:02","modified_gmt":"2024-05-06T18:24:02","slug":"metastatic-melanoma-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-melanoma-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies_697566.html","title":{"rendered":"Metastatic Melanoma Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1714995402.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic Melanoma Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1714995402.jpeg\" alt=\"Metastatic Melanoma Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Metastatic Melanoma Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Melanoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\"><em>The Metastatic Melanoma therapeutics market is anticipated to change in the coming years owing to the rise in the number of incident cases of Metastatic Melanoma, improvement in the diagnosis methodologies, the launch of emerging therapies, and incremental healthcare spending across the world. The pipeline of Metastatic Melanoma is quite robust, with several products available in the developmental stage.<\/em><\/p>\n<p style=\"text-align: justify;\">&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Metastatic Melanoma Pipeline Insight, 2024<\/strong><\/a>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Metastatic Melanoma Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>Metastatic Melanoma Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the emerging therapies for the&nbsp;<strong>treatment of Metastatic Melanoma<\/strong>&nbsp;and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li>\n<p>It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li>\n<p>It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the&nbsp;<strong>Metastatic Melanoma market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Melanoma Emerging Therapies &ndash; Mechanism of Action Types<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>CD8 positive T lymphocyte stimulant<\/p>\n<\/li>\n<li>\n<p>Ras protein inhibitor<\/p>\n<\/li>\n<li>\n<p>Immunostimulant<\/p>\n<\/li>\n<li>\n<p>PTK2 protein inhibitors<\/p>\n<\/li>\n<li>\n<p>Tumour necrosis factor-alpha stimulants<\/p>\n<\/li>\n<li>\n<p>T lymphocyte replacement<\/p>\n<\/li>\n<li>\n<p>T lymphocyte stimulant<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intra-articular<\/p>\n<\/li>\n<li>\n<p>Intraocular<\/p>\n<\/li>\n<li>\n<p>Intrathecal<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Ophthalmic<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Products have been categorized under various Molecule types, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oligonucleotide<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report covers the emerging products under different phases of clinical development &ndash;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Metastatic Melanoma Therapeutic Segment @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Melanoma Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment of Metastatic Melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of Metastatic melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered an option in some instances.<\/p>\n<p style=\"text-align: justify;\">To further improve the treatment scenario, there are approx.&nbsp;<strong>75+ key companies<\/strong>&nbsp;developing therapies for Metastatic Melanoma.&nbsp;<strong>Evaxion Biotech<\/strong>&nbsp;is leading the therapeutics market with its Metastatic Melanoma drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\"><strong>The Leading Companies in the Metastatic Melanoma Therapeutics Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Evaxion Biotech<\/p>\n<\/li>\n<li>\n<p>InxMed<\/p>\n<\/li>\n<li>\n<p>AiVita Biomedical<\/p>\n<\/li>\n<li>\n<p>Iovance Biotherapeutics<\/p>\n<\/li>\n<li>\n<p>Viralytics<\/p>\n<\/li>\n<li>\n<p>Merck &amp; Co.<\/p>\n<\/li>\n<li>\n<p>Neon Therapeutics<\/p>\n<\/li>\n<li>\n<p>BioNTech<\/p>\n<\/li>\n<li>\n<p>Bristol-Myers Squibb<\/p>\n<\/li>\n<li>\n<p>Ono Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Cytovation AS<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others<\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Melanoma Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>EVX 01: Evaxion Biotech<\/p>\n<\/li>\n<li>\n<p>IN 10018: InxMed<\/p>\n<\/li>\n<li>\n<p>AV MEL 1: AiVita Biomedical<\/p>\n<\/li>\n<li>\n<p>EVX 01: Evaxion Biotech&nbsp;<\/p>\n<\/li>\n<li>\n<p>Lifileucel: Iovance Biotherapeutics<\/p>\n<\/li>\n<li>\n<p>Fianlimab: Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>NKTR-214: Nektar Therapeutics<\/p>\n<\/li>\n<li>\n<p>IMO-2125: Idera Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li>\n<p>OBP 301: Oncolys BioPharma<\/p>\n<\/li>\n<li>\n<p>LN-144: Iovance Biotherapeutics&nbsp;<\/p>\n<\/li>\n<li>\n<p>Ampligen: Hemispherx Biopharma<\/p>\n<\/li>\n<li>\n<p>IPI-549 + Nivolumab: Infinity Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many More<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Metastatic Melanoma Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Metastatic Melanoma &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Metastatic Melanoma Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Metastatic Melanoma Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Metastatic Melanoma Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Metastatic Melanoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Metastatic Melanoma Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Metastatic Melanoma Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Metastatic Melanoma Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Metastatic Melanoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Metastatic Melanoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Metastatic Melanoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-pipeline-insight<\/strong><\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-melanoma-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-melanoma-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Metastatic Melanoma Pipeline Insights As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Melanoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-melanoma-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies_697566.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-697566","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=697566"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697566\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=697566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=697566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=697566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}